The results indicated that IL-19 mRNA levels were elevated by the CUS/DSS treatment (p=0.0201), while AAV-IL-19-GFP induced a dramatic increase of IL-19 in the colitis (p<0.0010) (Figure 6H, F(2,21)=68.3000, p<0.0010). This evidence concerns the gene IL19 and colitis.